Industry news

• Industry news
• Obstetrics and Gynecology

Quidel Announces FDA Clearance of Its RapidVue(R) hCG Pregnancy Lateral Flow Diagnostic Test

SAN DIEGO, Aug 31, 2010 --Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the sale of Quidel's RapidVue(R) hCG test, a lateral flow pregnancy immunoassay for the qualitative detection of human Chorionic Gonadotropin (hCG). more

Search the Pharmalicensing Industry news by keyword. Alternatively our advanced search allows you to query by category and therapeutic target.
Category	Therapeutic target
Deals and Alliances Development Financial Results Financings Intellectual Property Regulatory	Cardiovascular Dermatology Endocrine and Metabolic Gastroenterology Genitourinary Hematology Immunology and Allergy Infection Musculoskeletal Neurology Obstetrics and Gynecology Oncology Ophthalmology Psychiatry Pulmonary
To choose more then one item on the list hold CTRL button while selecting. To deselect items press CTRL button and deselect.

Most Viewed

Quidel Announces FDA Clearance of Its RapidVue(R) hCG Pregnancy Lateral Flow Diagnostic Test